Weight-based dosing and, presumably, patient response enabled providers to find the effective infliximab dose for IBD patients. The maintenance dose and administration frequency remained stable during the initial year.
This EMR study is among the first to present evidence of US physician practice prescribing patterns regarding initiation of oral antineoplastic agents and use of subsequent therapies in patients with advanced prostate cancer.
Groups of nude mice, with both hind footpads infected with 10(8) Mycobacterium leprae organisms, were treated with 4-week courses of different drug combinations. The effect treatment on each group was evaluated by subinoculating footpad homogenates from the treated mice into groups of normal and nude mice for subsequent regrowth, assessed 1 year later. A combination of rifampin (RMP) with clarithromycin (CLARI), minocycline (MINO), and ofloxacin (OFLO) resulted in the complete killing of M. leprae after 3 weeks of treatment. A combination of sparfloxacin (SPAR) and RMP also resulted in a similar bactericidal effect after 3 weeks of treatment. Other drug combinations showed variable effects. Very little or no effect was observed with any regimen if the treatment was given for less than 2 weeks. World Health Organization (WHO) multidrug therapy (MDT) given for 8 weeks was as effective as the two combinations described above. The results suggest that multidrug combinations consisting of RMP-OFLO (or SPAR)-CLARI (and/or MINO) are as effective as the WHO MDT for the treatment of experimental leprosy. Moreover, they imply that these combinations, which were found to be active in a 4-week experimental treatment protocol, could be administered as treatment to patients for a period of time shorter than the present 2-year regimen without a loss of effectiveness.
Background: Between 1987–1997, the demand for allogeneic blood (whole blood and packed RBC) in the US decreased due to concerns about safety of the blood supply1. Paradoxically, these concerns also led to a decrease in the available supply. During this same period, collection of allogeneic blood declined from 13.6 million to 11.9 million units, resulting in a 48% reduction in the margin between available supply and demand.1 Although both supply and demand for blood has since increased, the margin has further declined to only 6.1% in 2004 (allogeneic collection: 14.8 million units; transfusion: 13.9 million units)2. This situation is further exacerbated by procedures used for qualifying fully screened units. In 2004, 240,000 units were rejected after screening, leaving a margin of only 648,000 units available (4.5% of the supply). Given the introduction and adoption of treatments that reduce transfusions, such as erythropoiesis-stimulating agents (ESAs) for patients (pts) with chemotherapy-induced anemia (CIA), in the past 15 years, periodic shortages in the blood supply due to this limited surplus have been moderated. Purpose: To estimate the impact of limiting the use of ESAs for CIA on the US blood supply. Methods: A modeling simulation was employed using a top-down approach to compare the number of RBC units transfused in ESA-treated pts to the number of RBC units that would be transfused if ESAs were discontinued or limited in the same population. The excess number of RBC units that would be required if ESA treatment in CIA pts was limited was contrasted with the available marginal blood supply from 2004 (latest data available). Model inputs included incident cases of CIA pts treated with ESA, transfusion rates from clinical trials, and volume of RBC units required for ESA-treated and untreated pts. Data were obtained from published literature or expert opinion where published evidence was unavailable. Estimates were developed for multiple ESA reduction scenarios, and sensitivity analyses were conducted using a range of +/–10% for each input parameter. Results: Under the base case scenario, it was estimated that 492,002 incident CIA pts received a total of 372,809 RBC units despite ESA treatment. The model predicted that up to a third of the marginal US blood supply would be required to cover the incremental demand for blood that would arise from a 25% decrease in ESA use (incremental RBC units transfused: 118,602 units, sensitivity range: 63,030–210,110 units). For ESA use reductions of 50% and 75%, the model predicted 37% (237,203 units) and 55% (355,805 units) of the marginal US blood supply would be required, respectively. In the case of total cessation of ESA use for CIA, the available US blood supply could be exceeded (incremental demand: 474,407 units, sensitivity range: 252,119–840,441 units). Conclusions: This current model of blood demand showed limiting ESA use in CIA pts imposes considerable pressure on the available US blood supply given the small margin between usable blood and transfusion demand. This added pressure on the blood supply does not consider additional exacerbations due to regional and seasonal variation in the number of available units as well as donation frequency variations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.